Pharmacogenetics to guide cardiovascular drug therapy

Area of Science:

• Cardiovascular Medicine
• Pharmacogenetics
• Clinical Pharmacology

Background:

• Pharmacogenetic testing has become increasingly integrated into clinical practice over the last decade.
• Its primary application involves guiding cardiovascular therapies, with CYP2C19 genotyping for clopidogrel response being the most common use case.
• Other applications include guiding warfarin dosing and statin prescribing.

Purpose of the Study:

• To review the current evidence supporting the use of pharmacogenetic testing in cardiovascular medicine.
• To examine data from randomized controlled trials and observational studies on genotype-guided therapies.
• To discuss clinical implementation, guidelines, and future directions for cardiovascular pharmacogenetics.

Main Methods:

• Review of existing literature, including randomized controlled trials and observational studies.
• Analysis of evidence for genotype-guided cardiovascular drug prescribing.
• Examination of clinical guidelines and implementation examples.

Main Results:

• Substantial evidence supports genotype-guided antiplatelet therapy (e.g., clopidogrel) after percutaneous coronary intervention.
• Evidence is accumulating for other cardiovascular medications, but is not yet sufficient for widespread prescribing guidance.
• Pharmacogenetics holds potential for individualizing treatment regimens for complex diseases like heart failure.

Conclusions:

• Pharmacogenetic testing is a valuable tool for optimizing selected cardiovascular therapies.
• Continued research and sophisticated analytical approaches are necessary to expand its application, particularly for complex polygenic responses.
• The field of cardiovascular pharmacogenetics is poised for future growth and broader clinical integration.